Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Biogen

Revenues up 4% in the quarter driven by launch of SPINRAZA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen
3Q Revenues: $3.1 billion (+4%)
3Q Earnings: $1.2 billion (+19%)
YTD Revenues: $9.0 billion (+5%)   
YTD Earnings: $2.8 billion (-7%)
Comments: Multiple sclerosis revenues, including approximately $65 million in royalties on the sales of OCREVUS, were $2.3 billion in the quarter. TECFIDERA sales were $1.1 billion in the quarter, up 3%. Total Interferon sales were $662 million, down 7%. AVONEX sales were also down 7% to $538 million. TYSABRI revenues were $469 million, down 9%. PLEGRIDY sales were down 3% to $124 million. Revenue growth was driven by the launch of SPINRAZA for Spinal Muscular Atrophy, which contributed $271 million in global revenues. Biosimilar product sales were $101 million, up 229%.In 1Q17, Biogen completed the separation of its global hemophilia business, now Bioverativ. Revenues increased 13% excluding all hemophilia revenues from 3Q16. Hemophilia revenues include ELOCTATE and ALPROLIX, as well as royalty and contract manufacturing revenue related to Sobi.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters